RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Laurent Peyrin-Biroulet  ¹     J. Casey Chapman  ^{2, 3, 4}     Jean-Frédéric Colombel  ⁵     Flavio Caprioli  ⁶     Geert R. D'Haens  ⁷     Marc Ferrante  ⁸     Stefan Schreiber  ⁹     Raja Atreya  ¹⁰     Silvio Danese  ¹¹     James O. Lindsay  ¹²     Peter Bossuyt  ¹³     Britta Siegmund  ¹⁴     Peter Irving  ¹⁵     Remo Panaccione  ¹⁶     Ezequiel Neimark  ¹⁷     Kori Wallace     Toni Anschutz     Kristina Kligys     Rachel Duan  ¹⁸     Valerie Pivorunas     Xiu Huang     Sofie Berg     Lei Shu     Marla C. Dubinsky  ^19    
1 Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France
² Crohn's and Colitis Center at the Baton Rouge General, Baton Rouge, United States
³ GI Alliance, Baton Rouge, United States
⁴ Louisiana State University Health Sciences Center, Baton Rouge, United States
⁵ Icahn School of Medicine at Mount Sinai, USA, United States
⁶ University of Milan, Milano, Italy
⁷ AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
⁸ University Hospitals Leuven, Leuven, Belgium
⁹ University Hospital Schleswig-Holstein, Kiel, Germany
¹⁰ University Erlangen-Nuremberg, Erlangen, Germany
¹¹ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands
¹² Digestive Disorders Clinical Academic Unit, Barts & The London School of Medicine, London, United Kingdom
¹³ Imelda General Hospital, Bonheiden, Belgium
¹⁴ Charité - Universitätsmedizin Berlin, Berlin, Germany
¹⁵ Guy´s and St Thomas´ Hospital, London, United Kingdom
¹⁶ University of Calgary, Calgary, Canada
¹⁷ AbbVie, North Chicago, United States
¹⁸ Abbvie, North Chicago, United States
¹⁹ Mount Sinai Hospital, Mount Sinai, New York City, United States

Topic
IBD

Session
Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)